NVS
Price
$121.90
Change
-$1.91 (-1.54%)
Updated
Jul 3 closing price
Capitalization
197.93B
11 days until earnings call
SNYNF
Price
$98.33
Change
+$1.68 (+1.74%)
Updated
Jul 3 closing price
Capitalization
134.16B
Interact to see
Advertisement

NVS vs SNYNF

Header iconNVS vs SNYNF Comparison
Open Charts NVS vs SNYNFBanner chart's image
Novartis AG
Price$121.90
Change-$1.91 (-1.54%)
Volume$955.24K
Capitalization197.93B
Sanofi
Price$98.33
Change+$1.68 (+1.74%)
Volume$327
Capitalization134.16B
NVS vs SNYNF Comparison Chart in %
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNYNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. SNYNF commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and SNYNF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (NVS: $121.90 vs. SNYNF: $98.33)
Brand notoriety: NVS and SNYNF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 64% vs. SNYNF: 1%
Market capitalization -- NVS: $197.93B vs. SNYNF: $134.16B
NVS [@Pharmaceuticals: Major] is valued at $197.93B. SNYNF’s [@Pharmaceuticals: Major] market capitalization is $134.16B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileSNYNF’s FA Score has 1 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • SNYNF’s FA Score: 1 green, 4 red.
According to our system of comparison, NVS is a better buy in the long-term than SNYNF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 4 TA indicator(s) are bullish while SNYNF’s TA Score has 4 bullish TA indicator(s).

  • NVS’s TA Score: 4 bullish, 4 bearish.
  • SNYNF’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, SNYNF is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +1.31% price change this week, while SNYNF (@Pharmaceuticals: Major) price change was +0.97% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.13%. For the same industry, the average monthly price growth was +2.56%, and the average quarterly price growth was +9.33%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.13% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($198B) has a higher market cap than SNYNF($134B). NVS has higher P/E ratio than SNYNF: NVS (23.38) vs SNYNF (14.04). NVS YTD gains are higher at: 29.780 vs. SNYNF (3.398). NVS has higher annual earnings (EBITDA): 18.3B vs. SNYNF (13.8B). NVS has more cash in the bank: 14B vs. SNYNF (7.99B). SNYNF has less debt than NVS: SNYNF (21B) vs NVS (26.3B). NVS (46.7B) and SNYNF (46.1B) have equivalent revenues.
NVSSNYNFNVS / SNYNF
Capitalization198B134B148%
EBITDA18.3B13.8B133%
Gain YTD29.7803.398876%
P/E Ratio23.3814.04166%
Revenue46.7B46.1B101%
Total Cash14B7.99B175%
Total Debt26.3B21B125%
FUNDAMENTALS RATINGS
NVS vs SNYNF: Fundamental Ratings
NVS
SNYNF
OUTLOOK RATING
1..100
5020
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
8
Undervalued
PROFIT vs RISK RATING
1..100
13100
SMR RATING
1..100
2975
PRICE GROWTH RATING
1..100
4658
P/E GROWTH RATING
1..100
8089
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNYNF's Valuation (8) in the null industry is in the same range as NVS (18) in the Pharmaceuticals Major industry. This means that SNYNF’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for SNYNF (100) in the null industry. This means that NVS’s stock grew significantly faster than SNYNF’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNYNF (75) in the null industry. This means that NVS’s stock grew somewhat faster than SNYNF’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as SNYNF (58) in the null industry. This means that NVS’s stock grew similarly to SNYNF’s over the last 12 months.

NVS's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as SNYNF (89) in the null industry. This means that NVS’s stock grew similarly to SNYNF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSSNYNF
RSI
ODDS (%)
Bearish Trend 4 days ago
57%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
42%
Bullish Trend 4 days ago
47%
Momentum
ODDS (%)
Bullish Trend 4 days ago
46%
Bullish Trend 4 days ago
46%
MACD
ODDS (%)
Bullish Trend 4 days ago
63%
Bullish Trend 4 days ago
53%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
49%
Bullish Trend 4 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
45%
Bullish Trend 4 days ago
48%
Advances
ODDS (%)
Bullish Trend 5 days ago
49%
Bullish Trend 4 days ago
49%
Declines
ODDS (%)
Bearish Trend 17 days ago
45%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
40%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
40%
Bearish Trend 4 days ago
48%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNYNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BHK9.760.02
+0.21%
Blackrock Core BD TR
PXI43.390.09
+0.20%
Invesco Dorsey Wright Energy MomentumETF
FINE22.59N/A
N/A
Themes European Luxury ETF
USIG51.27N/A
N/A
iShares Broad USD Invm Grd Corp Bd ETF
BKGI38.54-0.21
-0.54%
BNY Mellon Global Infras Inc ETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-1.54%
GSK - NVS
65%
Loosely correlated
-0.86%
AZN - NVS
63%
Loosely correlated
-2.36%
JNJ - NVS
56%
Loosely correlated
+0.29%
PFE - NVS
55%
Loosely correlated
+0.24%
AMGN - NVS
48%
Loosely correlated
+0.47%
More

SNYNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNYNF has been loosely correlated with SNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if SNYNF jumps, then SNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNYNF
1D Price
Change %
SNYNF100%
+1.74%
SNY - SNYNF
37%
Loosely correlated
-2.05%
NVSEF - SNYNF
24%
Poorly correlated
-3.76%
AZN - SNYNF
23%
Poorly correlated
-2.36%
JNJ - SNYNF
22%
Poorly correlated
N/A
NVS - SNYNF
21%
Poorly correlated
-1.54%
More